Dupilumab for Aspirin-exacerbated Respiratory Disease
Status:
Completed
Trial end date:
2019-12-11
Target enrollment:
Participant gender:
Summary
Subjects with physician-diagnosed aspirin-exacerbated respiratory disease (AERD) who remain
unacceptably symptomatic with a SNOT 22 score > 18 despite routine medical therapy will be
enrolled in this single center, single-blinded study assessing the efficacy of dupilumab in
AERD.